Idiopathic short stature. Short stature, not elsewhere classified
Conditions
Interventions
The Children whose idiopathic short stature are approved by clinical and laboratory investigations will be enrolled into the study. Insulin like growth factor-1 (IGF-I) will be measured at the beginn
Treatment - Drugs
Sponsors
Vice chancellor for research of Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 12 Years
Inclusion criteria
Inclusion criteria: Objectives: To determine the effect of cypro Inclusion criteria: height > 2SD score (SDS) below the corresponding mean height for sex and age; no stigmata of puberty, systemic, endocrine and metabolic disorder especially growth hormone deficiency. Exclusion criteria: Genetic and karyotype abnormality; Turner syndrome; dysmorphic feature; skeletal abnormality; consumption of growth hormone and any drugs that affect on growth; any chronic systemic disorder .
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin-like growth factor-1. Timepoint: The baseline and 6 months after drug. Method of measurement: A blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Height growth velocity. Timepoint: before intervention and every 3 months after intervention. Method of measurement: calculation according to height and weight recorded in questionnaire.;Height standard deviation score. Timepoint: before intervention and 6 month after intervention. Method of measurement: calculation according to height and weight recorded in questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactProf. Maryam Razzaghy-Azar
Tehran University of Medical Sciences
Outcome results
None listed